AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France.
Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
Bone Marrow Transplant. 2017 Oct;52(10):1428-1435. doi: 10.1038/bmt.2017.122. Epub 2017 Jun 26.
Unrelated cord blood transplantation (UCBT) after a reduced intensity conditioning regimen (RIC) has extended the use of UCB in elderly patients and those with co-morbidities without an HLA-identical donor, although post-transplant relapse remains a concern in high-risk acute myeloid leukemia (AML) patients. HLA incompatibilities between donor and recipient might enhance the alloreactivity of natural killer (NK) cells after allogeneic hematopoietic stem-cell transplantation (HSCT). We studied the reconstitution of NK cells and KIR-L mismatch in 54 patients who underwent a RIC-UCBT for AML in CR in a prospective phase II clinical trial. After RIC-UCBT, NK cells displayed phenotypic features of both activation and immaturity. Restoration of their polyfunctional capacities depended on the timing of their acquisition of phenotypic markers of maturity. The incidence of treatment-related mortality (TRM) was correlated with low CD16 expression (P=0.043) and high HLA-DR expression (P=0.0008), whereas overall survival was associated with increased frequency of NK-cell degranulation (P=0.001). These features reflect a general impairment of the NK licensing process in HLA-mismatched HSCT and may aid the development of future strategies for selecting optimal UCB units and enhancing immune recovery.
无关脐带血移植(UCBT)在降低强度调理方案(RIC)后,扩大了在没有 HLA 相同供体的老年患者和合并症患者中使用 UCB 的范围,尽管在高危急性髓细胞白血病(AML)患者中,移植后复发仍然是一个问题。供体和受体之间的 HLA 不兼容可能会增强同种异体造血干细胞移植(HSCT)后自然杀伤(NK)细胞的同种异体反应性。我们在一项前瞻性 II 期临床试验中研究了 54 例在 CR 期接受 RIC-UCBT 治疗 AML 的患者的 NK 细胞重建和 KIR-L 错配。RIC-UCBT 后,NK 细胞表现出激活和不成熟的表型特征。它们多功能能力的恢复取决于获得成熟表型标志物的时间。治疗相关死亡率(TRM)的发生率与低 CD16 表达(P=0.043)和高 HLA-DR 表达(P=0.0008)相关,而总生存率与 NK 细胞脱颗粒的频率增加相关(P=0.001)。这些特征反映了 HLA 错配 HSCT 中 NK 许可过程的普遍受损,可能有助于制定未来选择最佳 UC 单位和增强免疫恢复的策略。